BioSpace News Archive

Akebia Therapeutics®, Inc. today announced that the company received a written response from the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) to Akebia’s Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) received in March 2022 for vadadustat.

Galecto, Inc. announced that Hans Schambye, M.D., Ph.D. will present at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.

CureVac N.V. (NASDAQ:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2023 and provided a business update.

TRACON Pharmaceuticals (NASDAQ: TCON) today announced the presentation of two posters at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting, being held June 2-6, 2023.

STRATA Skin Sciences, Inc. announced that the first six patients have been treated in the TheraClear®X open label, single-arm, clinical research study led by Glynis Ablon, MD, FAAD.

Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today that it will present positive preclinical efficacy data of ORY-4001 in a CMT model at the 2023 Peripheral Nerve Society (PNS) Annual Meeting.

BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases.

Spectral Medical Inc. today provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial.